Addiction · PsilocybinTrial Updateclinicalmid-term

Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression

Importance8/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/5/2026, 6:30:56 PM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The promising results of psilocybin-assisted psychotherapy in reducing relapse rates for individuals with Alcohol Use Disorder and depression could reshape treatment paradigms in addiction therapy. This trial highlights a significant opportunity for pharma companies to explore and invest in psychedelic therapies, which are currently underrepresented in the market. Regulatory context from FDA (Preventing Accidental Apoquel Chewable Overdoses) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).

Strategic Assessment

Pharma the outcomes of this trial as it may influence future treatment strategies and investment in psychedelic therapies for addiction. The strongest clinical anchor is Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms (ClinicalTrials.gov), entity match (psilocybin). In Addiction · Psilocybin, 1 regulatory and 2 competitive items passed relevance filtering for Psilocybin.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis.

Regulatory Outlook

Regulatory risk is concentrated around Preventing Accidental Apoquel Chewable Overdoses (FDA). Moderate corpus alignment.

Key Risks

Elevated medium regulatory exposure for Psilocybin could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Clinical risk from ClinicalTrials.gov (Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms) could weigh on Psilocybin through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

If psilocybin proves effective, it could capture a substantial share of the AUD treatment market, particularly among patients with co-occurring depression, thereby enhancing revenue potential for companies involved in its development.
Pharma the outcomes of this trial as it may influence future treatment strategies and investment in psychedelic therapies for addiction.

What Would Change This Assessment

This becomes more urgent if Follow the results of the ERPPAD trial comparing high-dose and low-dose psilocybin-assisted psychotherapy over the next 6 months.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Preventing Accidental Apoquel Chewable Overdoses
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.govhigh relevance
Entity match (psilocybin)
FDA document
View source
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
ClinicalTrials.govhigh relevance
Entity match (psilocybin)
FDA document
View source
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Lilly)
FDA document
View source
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Using Clinical Decision Support to Provide Social Risk-Informed Care for Opioid Use Disorder in the Emergency Department
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Use of Custom-Made Acrylic Palatal Stent to Minimize Donor Site Morbidity After Suture-Free Epithelialized Gingival Graft Harvesting: A Randomized Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Neuromodulation of Mood Switch Circuitry in Bipolar Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Psilocybin
Alcohol Use Disorder (AUD) market
psychedelic therapy sector

Commercial impact

medium

If psilocybin proves effective, it could capture a substantial share of the AUD treatment market, particularly among patients with co-occurring depression, thereby enhancing revenue potential for companies involved in its development.

Regulatory impact

medium

The outcomes of this trial may influence future regulatory approvals and guidelines for the use of psilocybin in treating AUD, particularly in populations with depressive symptoms, potentially leading to new treatment options.

What to watch

Follow the results of the ERPPAD trial comparing high-dose and low-dose psilocybin-assisted psychotherapy over the next 6 months.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.